Details of Disease

General Information of Disease (ID: DISCLMC4)

Disease Name Angina pectoris
Synonyms Prinzmetal's variant angina; angina inversa; variant angina pectoris; variant angina; Prinzmetal's angina
Disease Class BA40: Angina pectoris
Definition
A syndrome typically consisting of angina (cardiac chest pain) at rest that occurs in cycles. It is caused by vasospasm, a narrowing of the coronary arteries caused by contraction of the smooth muscle tissue in the vessel walls rather than directly by atherosclerosis (buildup of fatty plaque and hardening of the arteries). For a portion of patients Prinzmetal's angina may be a manifestation of vasospastic disorder and is associated with migraine, Raynaud's phenomenon or aspirin-induced asthma.|Potentially caused by mutations in smooth muscle K+ channel.nA syndrome typically consisting of angina (cardiac chest pain) at rest that occurs in cycles. It is caused by vasospasm, a narrowing of the coronary arteries caused by contraction of the smooth muscle tissue in the vessel walls rather than directly by atherosclerosis (buildup of fatty plaque and hardening of the arteries).
Disease Hierarchy
DISSHV10: Coronary vasospasm
DISCLMC4: Angina pectoris
ICD Code
ICD-11
ICD-11: BA40
ICD-9
ICD-9: 413
Expand ICD-11
'BA40.Z
Expand ICD-9
413
Disease Identifiers
MONDO ID
MONDO_0006021
MESH ID
D000788
UMLS CUI
C0002963
MedGen ID
295
HPO ID
HP:0001681
SNOMED CT ID
87343002

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 26 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Abciximab DMJO6GV Approved Monoclonal antibody [1]
Amlodipine DMBDAZV Approved Small molecular drug [2]
Amyl nitrite DMJKO05 Approved Small molecular drug [3]
Atenolol DMNKG1Z Approved Small molecular drug [4]
Atorvastatin DMF28YC Approved Small molecular drug [5]
Diltiazem DMAI7ZV Approved Small molecular drug [6]
Dronedarone DMA8FS5 Approved Small molecular drug [7]
Erythrityl Tetranitrate DMFGQ2S Approved Small molecular drug [8]
Isosorbide Dinitrate DMBI4JG Approved Small molecular drug [9]
Isosorbide Mononitrate DMYLMU0 Approved Small molecular drug [10]
Ivabradine DM0L594 Approved Small molecular drug [11]
LIDOFLAZINE DMV23GL Approved Small molecular drug [3]
Mepindolol DMUDWP9 Approved Small molecular drug [3]
Metoprolol DMOJ0V6 Approved Small molecular drug [12]
Molsidomine DM9MA8O Approved Small molecular drug [3]
Nadolol DMW6GVL Approved Small molecular drug [13]
Nicorandil DMIYJFV Approved Small molecular drug [14]
Nifedipine DMSVOZT Approved Small molecular drug [15]
Nipradilol DMA65ER Approved Small molecular drug [3]
Nitroglycerin DMQ2491 Approved Small molecular drug [16]
Pentaerythritol tetranitrate DMZ9MO5 Approved Small molecular drug [3]
Perhexiline DMINO7Z Approved Small molecular drug [17]
Propranolol DM79NTF Approved Small molecular drug [18]
Ranolazine DM0C9IL Approved Small molecular drug [19]
Trimetazidine DMHP9I2 Approved Small molecular drug [3]
Verapamil DMA7PEW Approved Small molecular drug [20]
------------------------------------------------------------------------------------
⏷ Show the Full List of 26 Drug(s)
This Disease is Treated as An Indication in 24 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Ad5FGF-4 DMVLWG7 Phase 3 NA [21]
Alferminogene tadenovec DMPH1RK Phase 3 NA [22]
DIPROTEVERINE HYDROCHLORIDE DMG8U6M Phase 3 Small molecular drug [23]
Generx DM1WMOK Phase 3 Gene therapy [24]
MPL-containing Pollinex allergy desensitization vaccine DMT35Z1 Phase 3 NA [25]
NM-702 DMDJLY9 Phase 3 Small molecular drug [26]
T89 DMC7E5X Phase 3 Small molecular drug [22]
Tilarginine acetate DMZBGI8 Phase 3 Small molecular drug [27]
VM-202 DMSW80U Phase 3 NA [28]
Zoniporide hydrochloride DM8L7JD Phase 3 Small molecular drug [29]
ACCLAIM DM0FGDO Phase 2 Small molecular drug [30]
Bimakalim DMBRL19 Phase 2 Small molecular drug [31]
FK-070 DMJSD5W Phase 2 Small molecular drug [32]
FK-409 DMKVXYS Phase 2 Small molecular drug [33]
Pegmusirudin DMPD3X6 Phase 2 NA [34]
Pirsidomine DMHI6GE Phase 2 Small molecular drug [35]
S-2150 DMTAX8B Phase 2 NA [36]
YM-758 DMU79X2 Phase 2 Small molecular drug [37]
YM-934 DM7KR4C Phase 2 Small molecular drug [38]
ZD-7288 DMPE2B9 Phase 2 Small molecular drug [39]
DT-TX-30 DM1FX09 Phase 1 NA [40]
F-15845 DMAH12E Phase 1 Small molecular drug [41]
Lefradafiban DMKZVLH Phase 1 Small molecular drug [42]
RGD-891 DMVJMF1 Phase 1 NA [43]
------------------------------------------------------------------------------------
⏷ Show the Full List of 24 Drug(s)
This Disease is Treated as An Indication in 47 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Epanolol DML1Y49 Discontinued in Preregistration Small molecular drug [44]
Isbogrel DM1B8NU Discontinued in Preregistration Small molecular drug [45]
Monatepil maleate DM9ADLQ Discontinued in Preregistration Small molecular drug [46]
PW-2101 DMD8K3B Discontinued in Preregistration NA [47]
Alinidine DMV2Y6L Discontinued in Phase 3 Small molecular drug [48]
ELGODIPINE HYDROCHLORIDE DMJOM31 Discontinued in Phase 3 Small molecular drug [49]
LAMIFIBAN DMHR1A7 Discontinued in Phase 3 Small molecular drug [50]
Mivazerol DMXT36M Discontinued in Phase 3 Small molecular drug [51]
ORBOFIBAN DMEDLXJ Discontinued in Phase 3 Small molecular drug [52]
Otamixaban DMGOPMK Discontinued in Phase 3 Small molecular drug [53]
SIBRAFIBAN DMZU1TV Discontinued in Phase 3 Small molecular drug [54]
BMS-180448 DMVBGIT Discontinued in Phase 2 Small molecular drug [55]
CARIPORIDE DMV2DY3 Discontinued in Phase 2 Small molecular drug [56]
Dopropidil DMMC6H7 Discontinued in Phase 2 Small molecular drug [57]
DX-9065a DMIXUMZ Discontinued in Phase 2 Small molecular drug [58]
FLOSATIDIL DMOCMXH Discontinued in Phase 2 Small molecular drug [59]
JTV-506 DMM8UNL Discontinued in Phase 2 Small molecular drug [60]
KRN-2391 DMZ1SEW Discontinued in Phase 2 Small molecular drug [61]
SINITRODIL DMMZ2JT Discontinued in Phase 2 Small molecular drug [62]
SL-87.0495 DM1CSOQ Discontinued in Phase 2 NA [63]
Y-27152 DMO90RN Discontinued in Phase 2 Small molecular drug [64]
ZD-2486 DMLFNMB Discontinued in Phase 2 Small molecular drug [65]
EG-011 DM17GMN Discontinued in Phase 1/2 NA [66]
BMS-191095 DMKFXTD Discontinued in Phase 1 Small molecular drug [67]
CERM-11956 DMQKRWO Discontinued in Phase 1 Small molecular drug [68]
CGS-22652 DMF05DL Discontinued in Phase 1 Small molecular drug [69]
Emakalim DM2V5XP Discontinued in Phase 1 Small molecular drug [70]
GP-668 DMJGE4V Discontinued in Phase 1 NA [71]
SR-33805 DM471IG Discontinued in Phase 1 Small molecular drug [72]
Bertosamil DM56WD3 Terminated Small molecular drug [74]
CD-832 DM5FEBQ Terminated NA [75]
Cetamolol DMIDFLV Terminated Small molecular drug [76]
Clentiazem DM8TQC9 Terminated Small molecular drug [77]
E-4080 DMZ1JKX Terminated Small molecular drug [78]
FR-144420 DM12JUE Terminated Small molecular drug [79]
FR-76830 DM7WGXS Terminated Small molecular drug [80]
Genevx DM6JNV3 Terminated NA [81]
Naltiazem hydrochloride DM7T2FO Terminated Small molecular drug [82]
Pranidipine DMI2N9H Terminated Small molecular drug [83]
R-56865 DMYTI3J Terminated Small molecular drug [84]
RP-66784 DM2GV78 Terminated Small molecular drug [85]
SIM-6080 DMBZ7SF Terminated Small molecular drug [86]
Siratiazem DMG90YW Terminated Small molecular drug [87]
SKF-96365 DMI79JN Terminated Small molecular drug [88]
SPM-3672 DMLS85Q Terminated Small molecular drug [89]
SPM-5185 DM1E9AC Terminated Small molecular drug [90]
Zatebradine DMNYKOT Terminated Small molecular drug [91]
------------------------------------------------------------------------------------
⏷ Show the Full List of 47 Drug(s)
This Disease is Treated as An Indication in 1 Preclinical Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
ONO-1301 DMMBIHO Preclinical Small molecular drug [73]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 3 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
DP-3005 DMXEVA2 Investigative NA [92]
GPG-290 DMRJ5OD Investigative NA [93]
HL-038 DMEUOGU Investigative NA [94]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 3 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
ABCC9 TTEF5MJ Strong Biomarker [95]
CLCN1 TTUYAF3 Strong Genetic Variation [96]
HTR1D TT6MSOK Strong Biomarker [97]
------------------------------------------------------------------------------------
This Disease Is Related to 3 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ERCC8 OT0T4WKI Strong Biomarker [98]
KCNJ8 OTZ8G8FE Strong Biomarker [99]
MED23 OTKZQT0R Strong Biomarker [95]
------------------------------------------------------------------------------------

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6584).
2 Amlodipine FDA Label
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Atenolol FDA Label
5 Atorvastatin FDA Label
6 Diltiazem FDA Label
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7465).
8 Drug information of Erythrityl Tetranitrate, 2008. eduDrugs.
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7051).
10 Isosorbide mononitrate FDA Label
11 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2357).
12 Metoprolol FDA Label
13 Nadolol FDA Label
14 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2411).
15 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2514).
16 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7053).
17 Perhexiline. Cardiovasc Drug Rev. 2007 Spring;25(1):76-97.
18 Propranolol FDA Label
19 Ranolazine FDA Label
20 Verapamil FDA Label
21 ClinicalTrials.gov (NCT01550614) Efficacy and Safety of Ad5FGF-4 for Myocardial Ischemia in Patients With Stable Angina Due to Coronary Artery Disease. U.S. National Institutes of Health.
22 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
23 Diproteverine (BRL 40015): a new type of calcium antagonist with potential antianginal properties. Eur J Pharmacol. 1991 Jan 17;192(3):317-27.
24 ClinicalTrials.gov (NCT01550614) Efficacy and Safety of Ad5FGF-4 for Myocardial Ischemia in Patients With Stable Angina Due to Coronary Artery Disease (ASPIRE). U.S. National Institutes of Health.
25 ClinicalTrials.gov (NCT00423787) Efficacy and Safety/Tolerability of Ragweed MATA MPL. U.S. National Institutes of Health.
26 Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials. 2011; 12: 134.
27 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003882)
28 ClinicalTrials.gov (NCT02427464) Phase 3 Gene Therapy for Painful Diabetic Neuropathy. U.S. National Institutes of Health.
29 Zoniporde: a potent and selective inhibitor of the human sodium-hydrogen exchanger isoform 1 (NHE-1). Cardiovasc Drug Rev. 2003 Spring;21(1):17-32.
30 ClinicalTrials.gov (NCT01116427) A Cooperative Clinical Study of Abatacept in Multiple Sclerosis. U.S. National Institutes of Health.
31 Lack of anti-ischemic efficacy of the potassium channel opener bimakalim in patients with stable angina pectoris. Cardiovasc Drugs Ther. 2004 Jan;18(1):37-46.
32 Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers. J Pharm Pharmacol. 1996 Apr;48(4):380-5.
33 The interaction of FK409, a novel nitric oxide releaser, and peripherally administered morphine during experimental inflammation. Anesth Analg. 1998 Feb;86(2):367-73.
34 ClinicalTrials.gov (NCT00074620) A Clinical Study to Assess the Safety of PEG-Hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis. U.S. National Institutes of Health.
35 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001151)
36 Pharmacodynamics of S-2150, a simultaneous calcium-blocking and alpha1-inhibiting antihypertensive drug, in rats. J Pharm Pharmacol. 2000 Mar;52(3):273-80.
37 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024920)
38 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001721)
39 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2359).
40 DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs. Basic Res Cardiol. 1997 Jun;92(3):181-90.
41 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023448)
42 ClinicalTrials.gov (NCT02264106) Influence of Pantoprazole on the Pharmacokinetics of Fradafiban After Multiple Oral Doses of Lefradafiban Over 5 Days in Healthy Subjects. U.S. National Institutes ofHealth.
43 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007824)
44 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000427)
45 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000413)
46 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001558)
47 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019361)
48 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000286)
49 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000324)
50 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003532)
51 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002725)
52 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007819)
53 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015497)
54 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006751)
55 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004365)
56 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004531)
57 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000432)
58 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004028)
59 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005965)
60 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006044)
61 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004022)
62 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005482)
63 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003670)
64 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001561)
65 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006364)
66 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030807)
67 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007109)
68 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000166)
69 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001983)
70 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001761)
71 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004432)
72 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002436)
73 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1964).
74 Bertosamil blocks HERG potassium channels in their open and inactivated states. Br J Pharmacol. 2002 Sep;137(2):221-8.
75 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001566)
76 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000160)
77 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000188)
78 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001760)
79 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006141)
80 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002286)
81 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013170)
82 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000300)
83 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000287)
84 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000253)
85 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003444)
86 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000149)
87 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001949)
88 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2441).
89 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002215)
90 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004308)
91 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2358).
92 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 536).
93 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607).
94 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
95 Episodic coronary artery vasospasm and hypertension develop in the absence of Sur2 K(ATP) channels.J Clin Invest. 2002 Jul;110(2):203-8. doi: 10.1172/JCI15672.
96 A Becker myotonia patient with compound heterozygosity for CLCN1 mutations and Prinzmetal angina pectoris.Neuromuscul Disord. 2012 Apr;22(4):355-60. doi: 10.1016/j.nmd.2011.10.024. Epub 2011 Dec 23.
97 5-HT1Dbeta receptor mediates the supersensitivity of isolated coronary artery to serotonin in variant angina.Chest. 1998 Jan;113(1):243-4. doi: 10.1378/chest.113.1.243.
98 Assessing Vessel Tone during Coronary Artery Spasm by Dual-Acquisition Multidetector Computed Tomography Angiography.Cardiology. 2018;139(1):25-32. doi: 10.1159/000478926. Epub 2017 Nov 23.
99 Absence of Kir6.1/KCNJ8 mutations in Italian patients with abnormal coronary vasomotion.Int J Mol Med. 2003 Oct;12(4):509-12.